Abed Agbarya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9636737/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1128-1137.	1.1	160
2	Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncology, The, 2021, 22, 581-583.	10.7	158
3	First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals, 2020, 13, 373.	3.8	49
4	Potential Mechanisms of Cancer-Related Hypercoagulability. Cancers, 2020, 12, 566.	3.7	47
5	Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers, 2021, 13, 4191.	3.7	34
6	Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. Journal of Clinical Medicine, 2021, 10, 5614.	2.4	21
7	Attitudes Among Nurses Toward the Integration of Complementary Medicine Into Supportive Cancer Care. Oncology Nursing Forum, 2017, 44, 428-434.	1.2	12
8	Anti-Inflammation Properties of Fruiting Bodies and Submerged Cultured Mycelia of Culinary-Medicinal Higher Basidiomycetes Mushrooms. International Journal of Medicinal Mushrooms, 2016, 18, 999-1009.	1.5	11
9	Maintaining consistent bladder filling during external beam radiotherapy for prostate cancer. Technical Innovations and Patient Support in Radiation Oncology, 2021, 17, 1-4.	1.9	11
10	FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Clinical Medicine, 2022, 11, 2475.	2.4	8
11	Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future. Cancers, 2021, 13, 4119.	3.7	7
12	Treatment of Rare Mutations in Patients with Lung Cancer. Biomedicines, 2021, 9, 534.	3.2	6
13	Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment. Journal of Clinical Medicine, 2022, 11, 1738.	2.4	4
14	Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer. Advances in Radiation Oncology, 2021, 6, 100603.	1.2	3
15	Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature. Anti-Cancer Drugs, 2021, 32, 456-459.	1.4	3
16	Novel nanotech antioxidant cocktail prevents medical diagnostic procedures ionizing radiation effects. Scientific Reports, 2021, 11, 5315.	3.3	2
17	Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?. Current Oncology, 2022, 29, 173-177.	2.2	2
18	Anti-androgen for myoepithelial tumor. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	1.4	0

#	Article	IF	CITATIONS
19	Automatic localization of the prostatic urethra for image guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2021, 19, 1-6.	1.9	ο
20	Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR Study Israel Medical Association Journal, 2021, 23, 759-765.	0.1	0